INDIVIDUAL PEPTIDE PROFILE
5-Amino-1MQ
A small quinolinium-class molecule, not a peptide, designed to selectively inhibit nicotinamide N-methyltransferase, an enzyme called NNMT that is involved in cellular energy metabolism and fat storage. It is studied almost entirely in mice.
WHAT IT IS
5-Amino-1MQ (5-amino-1-methylquinolinium) is a synthetic small molecule developed by researchers at the University of Texas Medical Branch as a selective, membrane-permeable inhibitor of NNMT.
NNMT is an enzyme that consumes a cellular methyl donor called S-adenosylmethionine (SAM). Earlier genetic work had shown that reducing NNMT activity in mice shifted fat tissue toward burning more energy, which made the enzyme an attractive drug target.
It is sold online as a research chemical marketed toward fat loss, but it is not a peptide, is not an approved medication, and has not been tested in a completed human clinical trial. FDA status: 5-Amino-1MQ is not FDA-approved for any indication.
WHAT RESEARCHERS ARE STUDYING IT FOR
Published research, entirely in cells and mice so far, has looked at:
- Reversal of diet-induced obesity in mice given daily doses over several weeks
- Improvements in glucose tolerance and insulin sensitivity in obese mice
- Adipose tissue metabolic activity and fat oxidation at the cellular level
- NNMT as a broader drug target in metabolic disease research, including work by larger pharmaceutical programs on related inhibitors
PROPOSED BIOLOGICAL MECHANISMS
The working hypothesis is that blocking NNMT preserves SAM levels inside fat cells, which shifts cellular metabolism toward greater energy expenditure and fat oxidation rather than storage.
In the original 2018 mouse study, this occurred without a change in how much the animals ate, suggesting an effect on energy use rather than appetite.
These findings come from a single research group's rodent work and related cell studies. They describe a mechanistic hypothesis, not a demonstrated human effect.
AREAS OF RESEARCH INTEREST
- Whether NNMT inhibition produces similar metabolic effects in humans as in mice
- Safety and pharmacokinetics of 5-Amino-1MQ specifically, which have not been published for humans
- Whether other NNMT-targeting approaches, including at least one discontinued pharmaceutical program, will reach human testing
- How this small molecule compares mechanistically to unrelated metabolic compounds sold alongside it
WHAT THE EVIDENCE CURRENTLY SUGGESTS
The animal evidence for NNMT inhibition affecting body weight and glucose handling is real and published in a peer-reviewed journal, but it is limited to one mouse model and a short treatment window.
There are no registered or published human clinical trials of 5-Amino-1MQ. Its human pharmacokinetics, effective dose, and safety profile are unknown.
Preclinical metabolic findings frequently fail to replicate in people, and NNMT-targeting drug programs at larger companies have reportedly been discontinued before reaching approval.
A mouse enzyme story, not a human weight-loss drug
AN INTERESTING TARGET IS NOT YET A PROVEN TREATMENT
NNMT is a legitimate and actively studied target in metabolic disease research, which is part of why 5-Amino-1MQ attracted attention outside the lab.
But a compound reversing obesity in mice under controlled conditions is a starting point for drug development, not evidence that it works, or is safe, in a person.
No company has taken 5-Amino-1MQ itself through registered human trials, which is a meaningful gap for anyone treating it as an established option.
Research Reality Check
What we know
5-Amino-1MQ is a small-molecule NNMT inhibitor shown, in one published mouse study, to reduce fat mass and improve insulin sensitivity without changing food intake, building on earlier genetic research linking NNMT to obesity.
What remains uncertain
Whether these effects occur in humans, what a safe or effective human dose would be, and what its side-effect profile looks like, since no human clinical trial data has been published.
Educational commentary, not personal testimonial
The Balanced Body Lifestyle Take
NNMT is one of the more interesting enzyme targets to come out of metabolism research in the last decade, and 5-Amino-1MQ is often the first name people bring up when they hear about it. We think the mouse data is worth understanding on its own terms, separate from how it is marketed.
If 5-Amino-1MQ has caught your attention, reach out to us. We can talk through what drew you to it, work through your questions, and look at what current research does and does not show.
QUESTIONS PEOPLE OFTEN ASK
SOURCES & FURTHER READING
- PubMed Central: Selective and membrane-permeable small molecule inhibitors of NNMT reverse high fat diet-induced obesity in mice
- PubMed Central: Roles of Nicotinamide N-Methyltransferase in Obesity and Type 2 Diabetes
- ClinicalTrials.gov: search results for NNMT inhibitor studies
- U.S. Food and Drug Administration: Drug Approval Process
Peptide Education Consultation
Interested in learning more about peptides? Schedule an educational consultation with Vince Angelo to discuss the information and ask questions.
Schedule an Educational ConsultationEDUCATIONAL NOTICE
The Balanced Body Lifestyle™ provides peptide and wellness information for educational purposes only. Content is intended to help readers better understand emerging research, established evidence and areas of scientific uncertainty. It is not medical advice, diagnosis, treatment guidance or a recommendation to use any medication, peptide or research compound. Decisions involving prescription medications or investigational compounds should be discussed with a qualified healthcare professional.
THE BALANCED BODY LIFESTYLE
A healthy life is built on balance.